Somatostatin analogs

Journal of Peptide Research

Volumn 58, Issue 2, 2001, Pages 91-107

  Janecka, A ^a   Zubrzycka, M ^a   Janecki, T ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Conformation studies; Peptidomimetics; Peptoid residues; Somatostatin receptor subtypes; Structure activity relationships

Indexed keywords

1 [3 [N (5 BROMO 2 PYRIDYL) N (3,4 DICHLOROBENZYL)AMINO]PROPYL] 3 [3 (4 IMIDAZOLYL)PROPYL]THIOUREA; ANGIOPEPTIN; ASS 51; ASS 52; ASS 53; BETA LACTAM DERIVATIVE; CYCLO(PROLYLPHENYLALANYL DEXTRO TRYPTOPHYLLYSYLTHREONYLPHENYLALANINE); CYCLO(PROLYLPHENYLALANYL DEXTRO TRYPTOPHYLLYSYLTHREONYLPHENYLALANYL); DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; L 054522; L 083087; L 779976; L 796778; L 797591; L 803087; L 817818; LANTHIONINE OCTREOTIDE; N [3 (AMINOMETHYL)CYCLOHEXYLMETHYL] 3 (1H INDOL 3 YL) 2 [(SPIRO[1H INDENE 1,4' PIPERIDIN] 1' YLCARBONYL)AMINO]PROPIONAMIDE; OCTREOTIDE; OCTREOTIDE AMIDE; PRL 2970; PROLINE DERIVATIVE; PTR 3046; SEGLITIDE; SEROTONIN RECEPTOR; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN[8 DEXTRO TRYPTOPHAN]; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE;

BINDING AFFINITY; DRUG POTENCY; DRUG SELECTIVITY; HISTORY; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, CORTICOTROPIN; RECEPTORS, MELANOCORTIN; RECEPTORS, OPIOID; SOMATOSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EQUUS ASINUS;

EID: 0034905424     PISSN: 1397002X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3011.2001.00873.x     Document Type: Review

References (113)

1. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
2. N-Terminally extended somatostatin. The primary structure of somatostatin-28
3. Processing of prosomatostatin
4. Somatostatin: Physiological and clinical significance
5. Somatostatin in the central nervous system: Physiology and pathological modifications
6. Classification and nomenclature of somatostatin receptors
7. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney
8. 5) human somatostatin receptor subtype
9. 5
10. Specific inhibition of rat pancreatic insulin and glucagon release by receptor-selective somatostatin analogs
11. Molecular biology of somatostatin receptors
12. 5
13. SRIF analogues inhibit the growth of pancreatic cancer by stimulating tyrosine phosphatase
14. The role of SRIF and its analogs in the diagnosis and treatment of tumors
15. Somatostatin analogs: Clinical application in relation to human somatostatin receptor subtypes
16. Development and applications of analogs of LRF and somatostatin
17. Somatostatin and its analogues in G.I. Tract, liver and pancreatic disorders
18. The role of somatostatin analogues in the treatment of refractory diarrhoea
19. Somatostatin analogs: Future directions
20. Somatostatin analogs in ectopic corticotropin production
21. The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumors
22. Therapeutic applications of somatostatin analogs
23. Somatostatin receptor ligands and their use in the treatment of endocrine disorders
24. Diverse roles of hypothalamic regulatory peptides
25. 8]-somatostatin: An analog of somatostatin more potent than the native molecule
26. Somatostatin
27. Somatostatin analogs with selected biologic activities
28. Somatostatin: Analogs with selected biological activities
29. Biologic and immunologic activities and applications of somatostatin analogs
30. Highly active cyclic and bicyclic somatostatin analogs of reduced ring size
31. A potent cyclic hexapeptide analogue of somatostatin
32. Somatostatin analogs which define the role of the lysine-9 amino group
33. Design of a highly active cyclic hexapeptide analogue of somatostatin
34. Conformational modifications of cyclic hexapeptide somatostatin analogs
35. A super active cyclic hexapeptide analog of somatostatin
36. SMS-201-995; a very potent and selective octapeptide analogue of somatostatin with prolonged action
37. From somatostatin to sandostatin: Pharmacodynamics and pharmacokinetics
38. Cyclic hexapeptides related to somatostatin. Synthesis and biological testing
39. 1H-NMR and molecular dynamics
40. Cyclic hexapeptide analogs of somatostatin containing bridge modifications
41. Main chain and side chain chiral methylated somatostatin analogs: Syntheses and conformational analyses
42. Syntheses and conformations of somatostatin-related cyclic hexapeptides incorporating specific α- and β-methylated residues
43. Somatostatin analogs containing o-aminomethylphenylacetic acid as a bridge unit
44. Conformation-directed design of cyclic somatostatins containing a βVI-turn mimetic
45. Design, synthesis and biological activity of potent and selective somatostatin analogues incorporating novel peptoid residues
46. Conformational analyses of somatostatin-related cyclic hexapeptides containing peptoid residues
47. Synthesis and binding potencies of cyclo-hexapeptide somatostatin analogs containing naphthylalanine and arylalkyl peptoid residues
48. Comparison of proteolytic succeptibilities of homologues L-amino acids and N-substituted glycine peptides and peptoid oligomers
49. Strength and cooperativity of contributions of surface salt bridges to protein stability
50. 4 lysozyme
51. Conformational equlibria in α- and δ-chymotripsin. Energetics and importance of the salt bridge
52. Synthesis and binding potencies of cyclic hexapeptide analogs of somatostatin incorporating acidic and basic peptoid residues
53. Preparation of N-Boc N-alkyl-glycines for peptoid synthesis
54. Peptoids: A modular approach to drug discovery
55. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin
56. Superactive octapeptide somatostatin analogs containing tryptophan at position 1
57. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (sst1-5)
58. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin
59. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue
60. Cloned somatostatin receptors: Identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides
61. Comparing conformations at low temperature and at high viscosity. Conformational study of somatostatin and two of its analogues in methanol and in ethylene glycol
62. Design of potent oxytocin antagonists featuring D-tryptophan at position 2
63. New analogs of somatostatin inhibiting effectively GH, glucagon and insulin levels
64. SMS 201-995, an octapeptide somatostatin analogue
65. Lanthionine-somatostatin analogs: Synthesis, characterization, biological activity, and enzymatic stability studies
66. A refined model for the somatostatin pharmacophore: Conformational analysis of lanthionine-sandostatin analogs
67. Syntheses and biological activities of sandostatin analogs containing stereochemical changes in positions 6 or 8
68. Development of a selective agonist at the somatostatin receptor SSTR1
69. A backbone cyclic, receptor 5 -selective somatostatin analogue: Synthesis, bioactivity, and nuclear magnetic resonance conformational analysis
70. Backbone cyclization. A new method for conferring conformational constraint on peptides
71. Sugar amino acids and carbohydrates as scaffolds and peptidomimetics
72. Nonpeptidal peptidomimetics with β-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist
73. De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing β-D-glucose as a novel scaffolding
74. Sugar amino acid as a novel peptide mimetic
75. Design and superactive and selective intedrin receptor antagonist containing RGD sequence
76. Synthesis and conformational analysis of linear and cyclic peptides containing sugar amino acids
77. Synthesis of novel proline and γ-lactam derivatives as non-peptide mimics of somatostatin/sandostatin
78. Synthesis and biological evaluation of a cyclo-β-tetrapeptide as a somatostatin analogue
79. The cyclo-β-tetrapeptide (β-Phe-β-HThr-β-HLys-β-HTrp): Synthesis, NMR structure in methanol solution, and affinity for human somatostatin receptors
80. β-Peptides: A surprise at every turn
81. Biological and pharmacokinetic studies with β-peptides
82. 3-amino acids and their use as building blocks for the solid-phase synthesis of β-peptides
83. 2) agonists
84. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2
85. 4 selectivity
86. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry
87. Identification and characterization of novel somatostatin antagonists
88. Identification and characterization of novel somatostatin antagonists
89. Potent antagonist of somatostatin. Synthesis and biology
90. Highly potent cyclic disulfide antagonist of somatostatin
91. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201, 995)
92. Sandostatin LAR: Pharmacokinetics, efficacy, and tolerability in acromegalic patients
93. Sandostatin LAR in acromegalic patients; long term treatment
94. Clinical results of long-term slow-release lanreotide treatment of acromegaly
95. Cardiological effect of a slow release lanreotide in normotensive and hypertensive acromegalic patients
96. Effects of a six-month lanreotide treatment on cardiac mass in acromegaly
97. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours
98. Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptors
99. Conformationally directed drug design
100. Design of peptide hormone and neurotransmitter analogs
101. Conformationally restricted analogs of somatostatin with high μ-opiate receptor specificity
102. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for μ-opioid receptors
103. Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: Identification of mu receptor-related functions
104. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific μ-opioid receptor antagonists with greatly reduced binding to somatostatin receptors
105. 13C n.m.r
106. A topographical model of μ-opioid and brain somatostatin receptor selective ligands
107. A new approach to receptor ligand design: Synthesis and conformation of a new class of potent and highly selective μ opioid antagonists utilizing tetrahydroisoquinoline carboxylic acid
108. Topographic design of peptide neurotransmitters and hormones on stable backbone templates: Relation of conformation and dynamics to bioactivity
109. Conformational restriction of Tyr and Phe side chains in opioid peptides: Information about preferred and bioactive side-chain topology
110. Opiate aromatic pharmacophore structure-activity relationships in CTAP analogs determined by topographical bias, two-dimension NMR, and biological activity assays
111. Design and bioactivities of melanotropic peptide agonists and antagonists: Design based on a conformationally constrained somatostatin template
112. Truncation studies of α-melanotropin peptides identify tripeptide analogs exhibiting prolonged agonist bioactivity